Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Cancer Therapies02:49

Cancer Therapies

7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

434
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
434
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

JAMA dermatology·2026
Same author

Response to Wang et al., "Time as a Substantial Confounder in Evaluating Integrated Multidisciplinary Care for Advanced Cutaneous Squamous Cell Carcinoma".

Journal of the American Academy of Dermatology·2026
Same author

Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial.

Nature communications·2026
Same author

PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.

Nature communications·2026
Same author

Clearance of circulating HPV DNA during chemoradiation using a next-generation sequencing liquid biopsy.

Oral oncology·2026
Same author

Multimodal Assessment of Biological Age Following Radiation Therapy Among Patients With Early-Stage NSCLC.

JAMA network open·2026

Related Experiment Video

Updated: Jul 26, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Radiotherapy Dose in Patients Receiving Immunotherapy.

Kelly J Fitzgerald1, Jonathan D Schoenfeld1

  • 1Brigham and Women's Hospital, Boston, MA.

Seminars in Radiation Oncology
|June 18, 2023
PubMed
Summary

Combining radiation therapy (RT) and immuno-oncology (IO) requires understanding optimal RT doses. Different doses impact tumor cells and the immune microenvironment, but reliably generating systemic effects like the abscopal effect remains challenging.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K

Related Experiment Videos

Last Updated: Jul 26, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Immunology

Background:

  • Combining radiation therapy (RT) with immuno-oncology (IO) agents is a promising strategy.
  • Optimal RT parameters for combination therapy are not yet established.
  • RT dose influences tumor immune microenvironment modulation and cell killing.

Purpose of the Study:

  • To review key clinical trials investigating RT and IO combinations.
  • To focus on the impact of varying RT doses on treatment outcomes.
  • To explore challenges and future directions in RT-IO therapy.

Main Methods:

  • Review of completed and ongoing clinical trials in RT and IO.
  • Analysis of RT dose fractionation and its effects on tumor response and toxicity.
  • Examination of strategies for generating systemic antitumor immunity (abscopal effect).

Main Results:

  • Low RT doses modulate the tumor immune microenvironment.
  • Intermediate RT doses kill tumor cells and modulate immunity.
  • Ablative RT doses eliminate tumor cells with potential immunomodulatory effects but risk toxicity.
  • Reliable generation of the abscopal effect has been difficult.
  • Newer trials explore whole-body or personalized RT with IO.

Conclusions:

  • RT dose selection is critical for optimizing RT-IO efficacy and managing toxicity.
  • Further research is needed to overcome challenges in achieving systemic effects.
  • Exploring RT-IO in earlier disease stages and in combination with other modalities shows promise.